
AstraZeneca reveals $50bn investment in US facilities
Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.
Newsletters and Deep Dive digital magazine
Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.
The FDA has rounded out its senior leadership by naming biopharma industry executive George Tidmarsh to the role of CDER director.
A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.
Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.
Editor's Picks
Newsletters and Deep Dive
digital magazine